Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
222 BERKELEY STREET, BOSTON, MA
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
13 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Rhythm Pharmaceuticals, Inc..

5 Aug 2026

Rhythm Pharmaceuticals, Inc. filed Form 10-Q

Rhythm Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

Rhythm Pharmaceuticals, Inc. reported Operating or financial results

Rhythm Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, Regulation FD disclosure, another company event, supporting financial statements or exhibits.

26 Jun 2026

Rhythm Pharmaceuticals, Inc. reported Shareholder voting results

Rhythm Pharmaceuticals, Inc. filed an 8-K covering shareholder voting results.

16 Jun 2026

Rhythm Pharmaceuticals, Inc. reported Regulation FD disclosure

Rhythm Pharmaceuticals, Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Cash and equivalents (USD)$65.61M
Total assets (USD)$437.27M
Total liabilities (USD)$219.97M
Shareholders' equity (USD)$102.98M
Long-term debt (USD)$93.40M
Debt due within a year (USD)$12.70M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
QuarterRevenue (USD)Operating incomeNet incomeDiluted EPS (USD)Filed
Q2 2026$71.26M−$48.55M−$49.30M−$0.7310-Q · 4 Aug 2026
Q1 2026$60.11M−$52.36M−$55.64M−$0.8310-Q · 5 May 2026
Q4 2025$57.25M−$47.06M$148.84MUnavailable10-K · 26 Feb 2026
Q3 2025$51.30M−$52.65M−$52.90M−$0.8210-Q · 4 Nov 2025
Q2 2025$48.50M−$45.30M−$46.63M−$0.7510-Q · 5 Aug 2025
Q1 2025$32.70M−$47.00M−$49.50M−$0.8110-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy
Target: $146.38
65.2% upside potential
📈
Strong Buy
Unavailable
👍
Buy
14
⏸️
Hold
1
📉
Sell
0
15 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 120.00–206.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
14
Sep 2026
Meeker David P
Director, President and CEO
Option exercise
$6.05 per share
50,000 shares
SEC Form 4
14
Sep 2026
Meeker David P
Director, President and CEO
Open-market sale
$102.67 per share
50,000 shares
SEC Form 4
31
Aug 2026
Smith Hunter C
Chief Financial Officer
Option exercise
$25.79 per share
57,187 shares
SEC Form 4
31
Aug 2026
Smith Hunter C
Chief Financial Officer
Open-market sale
$105.46 per share
62,774 shares
SEC Form 4
13
Aug 2026
Shulman Joseph
Chief Technical Officer
Option exercise
$6.80 per share
2,024 shares
SEC Form 4
13
Aug 2026
Shulman Joseph
Chief Technical Officer
Open-market sale
$119.75 per share
5,079 shares
SEC Form 4
13
Aug 2026
Garfield Alastair
Chief Scientific Officer
Open-market sale
$117.57 per share
7,763 shares
SEC Form 4
13
Aug 2026
Lee Jennifer Kayden
EVP, Head of North America
Option exercise
$17.62 per share
56,601 shares
SEC Form 4
13
Aug 2026
Lee Jennifer Kayden
EVP, Head of North America
Open-market sale
$117.38 per share
75,834 shares
SEC Form 4
12
Aug 2026
Mazabraud Yann
EVP, Head of International
Option exercise
$6.80 per share
46,625 shares
SEC Form 4

Top Shareholders

Ra Capital Management, L.P.
6,666,837 shares
0% change
6/30/2026
Vanguard Group Inc
6,210,916 shares
24.307% change
12/31/2025
Blackrock, Inc.
6,156,902 shares
-1.287% change
6/30/2026
Baker Bros. Advisors Lp
5,604,483 shares
0% change
6/30/2026
Primecap Management Co/Ca/
3,168,853 shares
-7.276% change
6/30/2026
Vanguard Portfolio Management Llc
3,136,895 shares
3.163% change
6/30/2026
Vanguard Capital Management Llc
3,005,977 shares
1.286% change
6/30/2026
Jpmorgan Chase & Co
2,652,746 shares
70.743% change
6/30/2026
Perceptive Advisors Llc
2,586,295 shares
8.952% change
6/30/2026
State Street Corp
2,573,529 shares
13.279% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 33 minutes ago